Consensus on clinical management of tumor-induced osteomalacia

Abstract

[4] Clinical diagnosis and management of TIO are challenging because knowledge about this condition is still restricted to a few specialized centers, leading to delay in diagnosis and appropriate treatment. See PDF] Future Prospects In terms of diagnosis, we need to propose some specific and easily-obtained criteria to help making suspicious diagnoses quickly in primary health care institutions. The mechanisms of tumorigenesis and FGF23 overproduction, detailed models and risk markers for stratifying severity, and refractory of TIO need to be further explored which would accurately benefit clinical management markedly. Wei-Bo Xia, Department of Endocrinology, Key Laboratory of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, NHC, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China E-Mail: [email protected]; Salvatore Minisola, Department of Internal Medicine and Medical Disciplines, Sapienza University of Rome, Rome 00161, Italy E-Mail: [email protected]; Jia-Jun Zhao, Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China E-mail: [email protected]; Zhen-Lin Zhang, Department of Osteoporosis and Bone Diseases, Shanghai Clinical Research Center of Bone Disease, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China E-mail: [email protected].